Levodopa-related motor complications-Phenomenology
2008; Wiley; Volume: 23; Issue: S3 Linguagem: Inglês
10.1002/mds.22021
ISSN1531-8257
AutoresSusan H. Fox, Anthony E. Lang,
Tópico(s)Genetic Neurodegenerative Diseases
ResumoMovement DisordersVolume 23, Issue S3 p. S509-S514 Research Article Levodopa-related motor complications—Phenomenology† Susan H. Fox MRCP (UK), PhD, Corresponding Author Susan H. Fox MRCP (UK), PhD [email protected] Division of Neurology, Toronto Western Hospital, Movement Disorders Clinic, University of Toronto, Toronto, Ontario, CanadaToronto Western Hospital, Movement Disorders Clinic, Division of Neurology, University of Toronto, 399 Bathurst Street MCL7-412, Toronto, ON M5T 2S8, CanadaSearch for more papers by this authorAnthony E. Lang MD, FRCPC, Anthony E. Lang MD, FRCPC Division of Neurology, Toronto Western Hospital, Movement Disorders Clinic, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this author Susan H. Fox MRCP (UK), PhD, Corresponding Author Susan H. Fox MRCP (UK), PhD [email protected] Division of Neurology, Toronto Western Hospital, Movement Disorders Clinic, University of Toronto, Toronto, Ontario, CanadaToronto Western Hospital, Movement Disorders Clinic, Division of Neurology, University of Toronto, 399 Bathurst Street MCL7-412, Toronto, ON M5T 2S8, CanadaSearch for more papers by this authorAnthony E. Lang MD, FRCPC, Anthony E. Lang MD, FRCPC Division of Neurology, Toronto Western Hospital, Movement Disorders Clinic, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this author First published: 09 September 2008 https://doi.org/10.1002/mds.22021Citations: 81 † Potential conflict of interest: Nothing to report. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Long term levodopa therapy in Parkinson's disease (PD) results in a range of problems. These include fluctuations in FD symptoms termed motor fluctuations, as well as non-motor symptoms, termed non-motor fluctuations. Here we review the phenomenology and methods of assessing these levodopa-related complications. © 2008 Movement Disorder Society REFERENCES 1 Ahlskog JE,Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448–458. 2 Quinn NP. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998; 51 ( Suppl 2) 25–29. 3 Muenter MD,Tyce GM. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971; 46: 231–239. 4 Nutt JG,Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996; 39: 561–573. 5 Obeso JA,Rodriguez-Oroz MC,Chana P,Lera G,Rodriguez M,Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000; 55 ( Suppl 4) S13–S20. 6 Olanow CW,Hauser RA,Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38: 771–777. 7 Hauser RA,Koller WC,Hubble JP,Malapira T,Busenbark K,Olanow CW. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2000; 15: 485–489. 8 Hauser RA,Holford NH. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2002; 17: 961–968. 9 Fahn S,Oakes D,Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498–2508. 10 Quattrone A,Zappia M,Aguglia U, et al. The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann Neurol 1995; 38: 389–395. 11 Nutt JG,Carter JH,Lea ES,Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002; 51: 686–693. 12 Colosimo C,Merello M,Hughes AJ,Sieradzan K,Lees AJ. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996; 60: 634–637. 13 Shoulson I,Glaubiger GA,Chase TN. On–off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in Parkinsonian patients. Neurology 1975; 25: 1144–1148. 14 Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiological aspects. In: CD Marsden, S Fahn, Editors. Movement disorders. London: Butterworth Scientific; 1982. p 123–145. 15 Fahn S. “On–off” phenomenon with levodopa therapy in parkinsonism: clinical and pharmacological correlations and the effects of intramuscular pyridoxine. Neurology 1974; 24: 431–444. 16 Melamed E,Bitton V. Delayed onset of responses to individual doses of L-dopa in Parkinsonian fluctuators: an additional side effect of long-term L-dopa therapy. Neurology 1984; 34 ( Suppl 2): 270. 17 Nutt JG,Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984; 7: 35–49. 18 Baruzzi A,Contin M,Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987; 10: 527–537. 19 Pierantozzi M,Pietroiusti A,Brusa L, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 2006; 66: 1824–1829. 20 Merello M,Lees AJ. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 1024–1026. 21 Nutt JG,Gancher ST,Woodward WR. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988; 38: 1553–1557. 22 Giladi N,McMahon D,Przedborski S, et al. Motor blocks in Parkinson's disease. Neurology 1992; 42: 333–339. 23 Fahn S. The freezing phenomenon in parkinsonism. Adv Neurol 1995; 67: 53–63. 24 Ambani LM,Van Woert MH. Start hesitation–a side effect of long-term levodopa therapy. N Engl J Med 1973; 288: 1113–1115. 25 Barbeau A. Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 1976; 33: 333–338. 26 Nutt JG. Levodopa-induced dyskinesia: review, observation and speculations. Neurology 1990; 40: 340–345. 27 Luquin MR,Scipioni O,Vaamonde J,Gershanik O,Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992; 7: 117–124. 28 Jankovic J,Nour F. Respiratory dyskinesia in Parkinson's disease. Neurology 1986; 36: 303–304. 29 Marconi R,Lefebvre-Caparros D,Bonnet AM,Vidailhet M,Dubois B,Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994; 9: 2–12. 30 Poewe WH,Lees AJ,Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988; 23: 73–78. 31 Bravi D,Mouradian MM,Roberts JW,Davis TL,Chase TN. End-of-dose dystonia in Parkinson's disease. Neurology 1993; 43: 2130–2131. 32 Melamed E. Early morning dystonia: a late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol 1979; 36: 308–310. 33 Cubo E,Gracies JM,Benabou R, et al. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol 2001; 58: 1379–1382. 34 Muenter MD,Sharpless NS,Tyce GM,Darley FL. Patterns of dystonia (I-D-I and D-I-D) in response to L-dopa therapy in Parkinson's disease. Mayo Clin Proc 1977; 52: 163–174. 35 Marsden CD,Parkes JD,Quinn N. Fluctuations of disability in Parkinson's disease–clinical aspects. In: CD Marsden, S Fahn, Editors. Movement disorders. London: Butterworth Scientific; 1982. p 96–122. 36 Freed CR,Greene PE,Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710–719. 37 Olanow CW,Goetz CG,Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403–414. 38 Pechevis M,Clarke CE,Vieregge P, et al. Trial study group. effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005; 12: 956–963. 39 Duvoisin RC. Variations in the “on-off” phenomena. Adv Neurol 1974; 5: 339–340. 40 Marsden CD,Parkes JD. “On–off” effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1: 292–296. 41 Mouradian MM,Juncos JL,Fabbrini G,Schlegel J,Bartko JJ,Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms Part II Ann Neurol 1988; 24: 372–378. 42 Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 672–681. 43 Struck LK,Rodnitzky RL,Dobson JK. Circadian fluctuations of contrast sensitivity in Parkinson's disease. Neurology 1990; 40: 467–470. 44 Bateman DE,Levett K,Marsden CD. Sleep benefit in Parkinson's disease. J Neurol Neurosurg Psychiarty 1999; 67: 384–385. 45 Khan NL,Graham E,Critchley P, et al. Parkin disease: a phenotypic study of a large case series. Brain 2003; 126: 1279–1292. 46 Riley DE,Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993; 43: 1459–1464. 47 Lang AE,Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998; 39: 1044–1053. 48 Shulman LM,Taback RL,Bean J,Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001; 16: 507–510. 49 Raudino F. Non motor off in Parkinson's disease. Acta Neurol Scand 2001; 104: 312–315. 50 Witjas T,Kaphan E,Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408–413. 51 Quinn NP,Koller WC,Lang AE,Marsden CD. Painful Parkinson's disease. Lancet 1986; 14: 1366–1369. 52 Nissenbaum H,Quinn NP,Brown RG,Toone B,Gotham AM,Marsden CD. Mood swings associated with the ‘on–off’ phenomenon in Parkinson's disease. Psychol Med 1987; 17: 899–904. 53 Giovannoni G,O'sullivan JD,Turner K,Manson AJ,Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423–428. 54 Lawrence AD,Evans AH,Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003; 2: 595–604. 55 Friedman JH. Punding on levodopa. Biol Psychiatry 1994; 36: 350–351. 56 Evans AH,Katzenschlager R,Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19: 397–405. 57 Defer GL,Widner H,Marie RM,Remy P,Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT–PD). Mov Disord 1999; 4: 572–584. 58 Widner H,Defer GL. Dyskinesias assessment: from CAPIT to CAPSIT. Core assessment program for intracerebral transplantations core assessment program for surgical interventional therapies. Mov Disord 1999; 14 ( Suppl 1) 60–66. 59 Hauser RA,Friedlander J,Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000; 23: 75–81. 60 Van Gerpen JA,Kumar N,Bower JH,Weigand S,Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990. Arch Neurol 2006; 63: 205–209. 61 Nyholm D,Kowalski J,Aquilonius SM. Wireless real-time electronic data capture for self-assessment of motor function and quality of life in Parkinson's disease. Mov Disord 2004; 19: 446–451. 62 Manson AJ,Brown P,O'sullivan JD,Asselman P,Buckwell D,Lees AJ. An ambulatory dyskinesia monitor. J Neurol Neurosurg Psychiatry 2000; 68: 196–201. 63 Van Someren EJ,Pticek MD,Speelman JD,Schuurman PR,Esselink R,Swaab DF. New actigraph for long-term tremor recording. Mov Disord 2006; 21: 1136–1143. Citing Literature Volume23, IssueS3Supplement: Levodopa Treatment and Motor Complications in Parkinson's Disease: Scientific Basis and Therapeutic Approaches- Guest Editors Dr. C. Warren Olanow, Dr. Andrew Lees, and Dr. Jose Obeso2008Pages S509-S514 ReferencesRelatedInformation
Referência(s)